CE Stock Analysis: Celanese | NYSE

Engineering Resins, Organic Acids, Textile Fibers, Adhesive Binders

Total Rating 43

Safety 75

Buy Signal -0.56

Chemicals
Industry Rotation: +2.0

Market Cap: 5.53B
Avg Turnover: 70.5M

Risk 3d forecast

Volatility52.2%

VaR 5^th Pctl7.98%

VaR vs Median-5.82%

Reward TTM

Sharpe Ratio0.67

Rel. Str. IBD42.7

Rel. Str. Peer Group40.2 pctl

Character TTM

Beta1.028

Beta Downside1.480

Hurst Exponent0.420

Choppyness66.4%

Drawdowns 3y

Max DD78.96%

CAGR/Max DD-0.33

CAGR/Mean DD-0.53

EPS (Earnings per Share)

EPS CAGR: -25.51%
EPS Trend: -85.0%

Last SUE: 0.55
Qual. Beats: 0

Revenue

Rev. CAGR: -4.67%
Rev. Trend: -91.6%

Last SUE: -1.02
Qual. Beats: -1

Warnings

High Debt/EBITDA With Thin Interest Coverage

Below Avwap Earnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.7 years of data

Jan +0.1% 7

Feb -2.5% 8

Mar +0.4% 10

Apr +1.1% 5

May +1.1% 8

Jun -3.7% 18

Jul -0.1% 7

Aug -1.6% 19

Sep +2.1% 6

Oct -1.2% 14

Nov +6.3% 29

Dec -1.4% 9

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CE Celanese

Celanese Corporation is a global producer and seller of engineered polymers, operating through two segments: Engineered Materials and Acetyl Chain. The Engineered Materials segment supplies high-performance polymers and thermoplastics (such as polyoxymethylene, nylon compounds, liquid crystal polymers, and thermoplastic elastomers) used across automotive, consumer electronics, medical, construction, energy storage, and industrial applications. The Acetyl Chain segment provides acetyl-based products-including acetic acid, vinyl acetate monomers, acetate tows, and emulsions-that serve as building blocks for adhesives, coatings, flexible packaging, paints, textiles, and pharmaceutical applications. The company sells under a broad portfolio of brands (including Hostaform, Celanex, Santoprene, Hytrel, and Zytel) via direct sales, distributors, and OEMs, and was founded in 1912 with headquarters in Irving, Texas.

As a specialty chemicals company within the Materials sector, Celanese occupies a vertically integrated position in the acetyl value chain, converting basic feedstocks like ethylene and methanol into higher-margin intermediates and downstream polymers. Its dual-segment model pairs commodity-scale acetyl production with differentiated engineered materials, allowing the business to serve both volume-driven industrial customers and performance-driven specialty end markets.

Headlines to Watch Out For

Acetyl chain margins pressured by weak acetic acid pricing
Engineered Materials demand softens on automotive destocking
Deleveraging from M&M acquisition remains key investor focus

Piotroski VR-10 (Strict) 3.0

Net Income: 262.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.83 > 1.0
NWC/Revenue: 11.57% < 20% (prev 24.34%; Δ -12.76% < -1%)
CFO/TA 0.05 > 3% & CFO 1.07b > Net Income 262.0m
Net Debt (10.9b) to EBITDA (1.58b): 6.91 < 3
Current Ratio: 1.26 > 1.5 & < 3
Outstanding Shares: last quarter (110.2m) vs 12m ago 0.55% < -2%
Gross Margin: 20.13% > 18% (prev 21.33%; Δ -1.19% > 0.5%)
Asset Turnover: 45.70% > 50% (prev 43.80%; Δ 1.90% > 0%)
Interest Coverage Ratio: 1.04 > 6 (EBIT TTM 791.0m / Interest Expense TTM 758.0m)

Altman Z'' 2.45

A: 0.05 (Total Current Assets 5.49b - Total Current Liabilities 4.35b) / Total Assets 20.9b
B: 0.48 (Retained Earnings 10.1b / Total Assets 20.9b)
C: 0.04 (EBIT TTM 791.0m / Avg Total Assets 21.6b)
D: 0.26 (Book Value of Equity 4.22b / Total Liabilities 16.3b)
Altman-Z'' = 2.45 = A

Beneish M -3.01

DSRI: 0.92 (Receivables 1.58b/1.70b, Revenue 9.85b/9.71b)
GMI: 1.06 (GM 21.33% / 20.13%)
AQI: 1.04 (AQ_t 0.49 / AQ_t-1 0.48)
SGI: 1.01 (Revenue 9.85b / 9.71b)
TATA: -0.04 (NI 262.0m - CFO 1.07b) / TA 20.9b)
Beneish M = -3.01 (Cap -4..+1) = AA

What is the price of CE shares?

As of November 08, 2026, the stock is trading at USD 46.49 with a total of 1,309,964 shares traded. Over the past week, the price has changed by -5.70%, over one month by +3.72%, over three months by +5.85% and over the past year by +29.05%.

Current recommended Stop Loss: 41.90 (which is 9.9% or 2.3 ATR below the current price).

Is CE a buy, sell or hold?

Celanese has received a consensus analysts rating of 4.06. Therefore, it is recommended to buy CE.

StrongBuy: 9
Buy: 1
Hold: 8
Sell: 0
StrongSell: 0

What are the forecasts/targets for the CE price?

Analysts Target Price	61.3	31.9%

Celanese (CE) - Fundamental Data Overview as of 05 November 2026

Market Cap USD = 5.53b (5.53b USD * 1.0 USD.USD)
P/E Forward = 9.5694
P/S = 0.5691
P/B = 1.2984
P/EG = 1.7421
Revenue TTM = 9.85b USD
EBIT TTM = 791.0m USD
EBITDA TTM = 1.58b USD
Long Term Debt = 11.4b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.41b USD (from shortTermDebt, last quarter)
Debt = 12.3b USD (from shortLongTermDebtTotal, last quarter) + Leases 390.0m
Net Debt = 10.9b USD (calculated: Debt 12.3b - CCE 1.36b)
Enterprise Value = 16.4b USD (5.53b + Debt 12.3b - CCE 1.36b)
Interest Coverage Ratio = 1.04 (Ebit TTM 791.0m / Interest Expense TTM 758.0m)
EV/FCF = 20.69x (Enterprise Value 16.4b / FCF TTM 794.0m)
FCF Yield = 4.83% (FCF TTM 794.0m / Enterprise Value 16.4b)
FCF Margin = 8.06% (FCF TTM 794.0m / Revenue TTM 9.85b)
Net Margin = 2.66% (Net Income TTM 262.0m / Revenue TTM 9.85b)
Gross Margin = 20.13% ((Revenue TTM 9.85b - Cost of Revenue TTM 7.87b) / Revenue TTM)
Gross Margin QoQ = 21.09% (prev 22.46%)
Tobins Q-Ratio = 0.78 (Enterprise Value 16.4b / Total Assets 20.9b)
Interest Expense / Debt = 6.18% (Interest Expense 758.0m / Debt 12.3b)
Taxrate = 13.03% (43.0m / 330.0m)
NOPAT = 687.9m (EBIT 791.0m * (1 - 13.03%))
Current Ratio = 1.26 (Total Current Assets 5.49b / Total Current Liabilities 4.35b)
Debt / Equity = 2.91 (Debt 12.3b / totalStockholderEquity, last quarter 4.22b)
Debt / EBITDA = 6.91 (Net Debt 10.9b / EBITDA 1.58b)
Debt / FCF = 13.73 (Net Debt 10.9b / FCF TTM 794.0m)
Total Stockholder Equity = 4.12b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.22% (Net Income 262.0m / Total Assets 20.9b)
RoE = 6.35% (Net Income TTM 262.0m / Total Stockholder Equity 4.12b)
RoCE = 5.10% (EBIT 791.0m / Capital Employed (Equity 4.12b + L.T.Debt 11.4b))
RoIC = 3.93% (NOPAT 687.9m / Invested Capital 17.5b)
WACC = 6.53% (E(5.53b)/V(17.8b) * Re(9.09%) + D(12.3b)/V(17.8b) * Rd(6.18%) * (1-Tc(0.13)))
Discount Rate = 9.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.48 | Cagr: 0.26%
[DCF] Terminal Value 73.10% ; FCFF base≈886.0m ; Y1≈777.0m ; Y5≈627.8m
[DCF] Fair Price = N/A (negative equity: EV 10.1b - Net Debt 10.9b = -825.8m; debt exceeds intrinsic value)
EPS Correlation: -85.03 | EPS CAGR: -25.51% | SUE: 0.55 | # QB: 0
Revenue Correlation: -91.61 | Revenue CAGR: -4.67% | SUE: -1.02 | # QB: -1
EPS current Quarter (2027-03-31): EPS=1.36 | Chg30d=+3.40% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=6.02 | Chg30d=+0.68% | Revisions=-12% | GrowthEPS=+51.1% | GrowthRev=+3.6%
EPS next Year (2027-12-31): EPS=6.02 | Chg30d=-2.04% | Revisions=-36% | GrowthEPS=+0.1% | GrowthRev=+0.6%
[Analyst] Revisions Ratio: -28% (up=5, down=10)